Evidence map›Paper›PMID 39008806›Full record

ArticleJCO oncology practice2024

Electronic Patient-Reported Outcome-Driven Symptom Management by Oncology Pharmacists in a Majority-Minority Population: An Implementation Study.

Alexandre Chan, Ding Quan Ng, Daniela Arcos, Matthew Heshmatipour, Benjamin J Lee, Alison Chen, Lan Duong, Linda Van, Thomas Nguyen, Vuong Green and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in JCO oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07787806 (A Randomized Controlled, Type 1 Hybrid Effectiveness-implementation Trial Study to Compare the Effectiveness of a Patient-Reported Outcomes), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07787806 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized Controlled, Type 1 Hybrid Effectiveness-implementation Trial Study to Compare the Effectiveness of a Patient-Reported Outcomes (PRO)-Driven Culturally Grounded Supportive Care Navigation in Reducing Healthcare Disparities Among Hispanic/Latinx Patients Receiving Anticancer Therapies

TypeinterventionalSponsorUniversity of California, IrvineRan2026 to 2028Enrolled72ConditionsCancerArmsPatient-Reported Outcomes (PRO)-driven supportive care navigation
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Incidence and predictors of immune checkpoint inhibitor treatment-related cognitive impairment in a racial and ethnic diverse population.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  4. Pharmacist-led interventions associated with symptoms identified by electronic patient-reported outcome battery: A descriptive study.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexandre ChanSchool of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA.ORCID 0000-0003-4391-4219
Ding Quan NgSchool of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA.ORCID 0000-0002-0754-7901
Daniela ArcosSchool of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA.ORCID 0000-0002-7634-8818
Matthew HeshmatipourSchool of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA.ORCID 0000-0002-2831-5106
Benjamin J LeeSchool of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA.ORCID 0000-0002-1678-1345
Alison ChenDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, Orange, CA.ORCID 0009-0009-0129-8711
Lan DuongDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, Orange, CA.
Linda VanDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, Orange, CA.
Thomas NguyenDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, Orange, CA.
Vuong GreenDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, Orange, CA.
Daniel HoangSchool of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere is a lack of systematic solutions to manage supportive care issues in racial/ethnic minorities (REM) receiving treatment for cancer. We developed and implemented an electronic patient-reported outcome (ePRO)-driven symptom management tool led by oncology pharmacists in a majority-minority cancer center located in Southern California. This study was designed to evaluate the implementation outcomes of our multilevel intervention.

methodsThis was a prospective, pragmatic, implementation study conducted between July 2021 and June 2023. Newly diagnosed adult patients with cancer receiving intravenous anticancer therapies completed symptom screening using ePRO that consists of the Patient-Reported Outcomes Measurement Information System measures at each infusion visit during the study. ePRO results were presented to an oncologist pharmacist for personalized symptom management and treatment counseling. The RE-AIM framework was used to guide implementation outcomes. Differences in symptom trajectories and clinical outcomes between groups were tested using generalized estimating equations.

resultsWe screened 388 patients of whom 250 were enrolled (acceptance rate: 64.4%), with 564 assessments being completed. The sample consisted of non-Hispanic White (NHW, 42.4%), Hispanic/Latinx (H/L, 30.8%), and non-Hispanic Asian (20.4%), with one (21.6%) of five participants preferring speaking Spanish. Compared with NHW, H/L participants had greater odds of reporting mild to severe pain interference (odds ratio [OR], 1.91 [95% CI, 1.18 to 3.08];

conclusionOur multilevel ePRO-driven intervention led by oncology pharmacists helps facilitate symptom assessments and management and potentially reduce health disparities among REM.

Indexed as

NeoplasmsPatient Reported Outcome MeasuresPharmacistsAdultAgedFemaleHumansMaleMiddle AgedMinority GroupsProspective Studies

Identifiers

PMID39008806
PMCPMC11649175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.